TS-1 combination OD tablet specific use-results survey "To evaluate safety of tegafur, gimeracil, oteracil potassium combination OD tablet"
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2017
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Gastric cancer
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical Company
- 12 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2016 New trial record